Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.46 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.40 |
| ▸ | FUT8 | Q9BYC5 | 1/20 | 0.37 |
| ▸ | CHAT | P28329 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13152005 | 0.92 | ENPP2 (0.46) | ENPP2PHLPP2FUT8CHATKMT2A | |
| SCHEMBL13151907 | 0.89 | PTGS2 (0.42) | ENPP2PHLPP2BRD4PTGS2MEN1 | |
| SCHEMBL13151849 | 0.88 | ENPP2 (0.39) | ENPP2PHLPP2FUT8CHATBRD4 | |
| SCHEMBL13151865 | 0.88 | ENPP2 (0.57) | ENPP2PHLPP2FUT8CHATMEN1 | |
| SCHEMBL13151869 | 0.87 | ENPP2 (0.49) | ENPP2PHLPP2FUT8CHATMEN1 | |
| SCHEMBL13151859 | 0.86 | ENPP2 (0.47) | ENPP2PHLPP2FUT8CHATMEN1 | |
| SCHEMBL13151899 | 0.84 | ENPP2 (0.52) | ENPP2PHLPP2FUT8CHATBRD4 | |
| SCHEMBL13879847 | 0.83 | ENPP2 (0.51) | ENPP2PHLPP2FUT8CHATBRD4 | |
| SCHEMBL13151992 | 0.82 | ENPP2 (0.53) | ENPP2PHLPP2FUT8BRD4MEN1 | |
| SCHEMBL13151909 | 0.82 | ENPP2 (0.49) | ENPP2PHLPP2FUT8CHATMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288280-A1 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-7799122-B2 | Azo compounds | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799122-B2 | Azo compounds | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20100151212-A1 | Azo compounds | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100151212-A1 | Azo compounds | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| WO-2007012828-A2 | AZO COMPOUNDS | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288280-A1 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | CTH, LNPEP, CARS1 | ENPP2 4311/4885PHLPP2 1984/4885FUT8 370/4885 |
| US-20100151212-A1 | Azo compounds | PAH, CYP1A1, RB1 | ENPP2 3818/4885PHLPP2 2220/4885FUT8 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.